1. Shalnova S. A., Deev A. D., Oganov R. G. Factors influencing cardiovascular mortality in Russian population. Cardiovascular Therapy and Prevention. 2005;4 (1):4-9. [Rusian: Shal'nova S. A., Deev A. D., Oganov R. G. Faktory, vliyayushchie na smertnost' ot serdechno-sosudistykh zabolevanii v rossiiskoi populyatsii. Kardiovaskulyarnaya terapiya i profilaktika. 2005; 4(1):4-9]
2. White SJ, Newby AC, Johnson TW. Endothelial erosion of plaques as a substrate for coronary thrombosis. Thrombosis and Haemostasis. 2016;115(03):509-19. https://doi.org/10.1160/th15-09-0765
3. Ducrocq G, Bhatt D, Labreuche J, Corbalan R, Porath A, Gao R et al. Geographic differences in outcomes in outpatients with established atherothrombotic disease: results from the REACH Registry. European Journal of Preventive Cardiology. 2014;21(12):1509-16. https://doi.org/10.1177/2047487313501278
4. Antithrombotic Trialists’ Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ (Clinical research ed.). 2002;324(7329):71-86. PMID: 11786451
5. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet (London, England). 1988;2(8607):349-60. PMID: 2899772
6. Xing L, Yamamoto E, Sugiyama T, Jia H, Ma L, Hu S et al. EROSION Study (Effective Anti-Thrombotic Therapy without Stenting: Intravascular Optical Coherence Tomography-Based Management in Plaque Erosion): A 1-Year Follow-Up Report. Circulation: Cardiovascular Interventions. 2017;10(12):pii:e005860. https://doi.org/10.1161/CIRCINTERVENTIONS.117.005860
7. Komajda M, Weidinger F, Kerneis M, Cosentino F, Cremonesi A, Ferrari R et al. EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). European Heart Journal. 2016;37(2):152-60. https://doi.org/10.1093/eurheartj/ehv437
8. Ridker PM, Manson JE, Gaziano JM, Buring JE, Hennekens CH. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Annals of Internal Medicine. 1991;114(10):835-9. PMID: 2014943
9. Juul-Möller S, Edvardsson N, Jahnmatz B, Rosén A, Sørensen S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet (London, England). 1992;340(8833):1421-5. PMID: 1360557
10. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal. 2016;37(3):267- 315. https://doi.org/10.1093/eurheartj/ehv320
11. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal. 2014;35(37):2541-619. https://doi.org/10.1093/eurheartj/ehu278
12. Hawkey CJ, Langman MJS. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut. 2003;52(4):600-8. PMID: 12631678
13. Yakovenko E. P., Yakovenko A. V., Agafonova N. A., Ovchinnikova N. I., Ivanov A. N., Aldiyarova M. A. et al. Peptic ulcers, pathogenetic approaches to therapy. Pharmateca. 2008;13:62-8. [Russian: Yakovenko E. P., Yakovenko A. V., Agafonova N. A., Ovchinnikova N. I., Ivanov A. N., Aldiyarova M. A. i dr. Pepticheskie yazvy, patogeneticheskie podkhody k terapii. Farmateka. 2008;13:62-8]
14. Takeuchi K. Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility. World Journal of Gastroenterology. 2012;18(18):2147-60. https://doi.org/10.3748/wjg.v18.i18.2147
15. Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. The Lancet. 2018;392(10152):1036-46. https://doi.org/10.1016/S0140-6736(18)31924-X
16. Feldman M. Sleisenger & Fortran’s Gastrointestinal and Liver Disease: in 2 vol. - Philadelphia: Saunders; 2046 p. ISBN 978-0-7216-6291-6
17. Karateev A. E., Nasonov E. L., Yakhno N. N., Ivashkin V. T., Chichasova N. V., Alekseeva L. I. et al. Clinical guidelines “Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice”. Modern Rheumatology Journal. 2015;9(1):4-23. [Russian: Karateev A. E., Nasonov E. L., Yakhno N. N., Ivashkin V. T., Chichasova N. V., Alekseeva L. I. i dr. Klinicheskie rekomendatsii «Ratsional'noe primenenie nesteroidnykh protivovospalitel'nykh preparatov (NPVP) v klinicheskoi praktike». Sovremennaya revmatologiya. 2015;9(1):4-23]. https://doi.org/10.14412/1996-7012-2015-1-4-23
18. Mallen SR, Essex MN, Zhang R. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs. Current Medical Research and Opinion. 2011;27(7):1359-66. https://doi.org/10.1185/03007995.2011.581274
19. Lanas A. A review of the gastrointestinal safety data - a gastroenterologist’s perspective. Rheumatology (Oxford, England). 2010;49(Suppl 2):ii3-10. https://doi.org/10.1093/rheumatology/keq058
20. Bulakhova E. Yu., Korennova O. Yu., Kozyreva V. A., Kurochkina S. D., Murotova S. A. Reduction of gastro-intestinal adverse effect risk in long-term therapy with acetylsalicylic acid. Cardiovascular Therapy and Prevention. 2010;9(4):41-4. [Russian: Bulakhova E. Yu., Korennova O. Yu., Kozyreva V. A., Kurochkina S. D., Murotova S. A. Vozmozhnosti snizheniya razvitiya gastroduodenal'nykh oslozhnenii pri dlitel'nom ispol'zovanii preparatov atsetilsalitsilovoi kisloty. Kardiovaskulyarnaya terapiya i profilaktika. 2010;9(4):41-4]
21. Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development aſter treatment for Helicobacter pylori: a population-based study. Gut. 2018;67(1):28-35. https://doi.org/10.1136/gutjnl-2017-314605
22. Baglikov A. N., Rafalsky V. V. The Value of Compliance During Chronic Administration of Acetylsalicylic Acid in Patients with Acute Coronary Syndrome: Results of The Study FORPOST. Kardiologiia. 2012;52(9):22-8. [Russian: Baglikov A. N., Rafal'skii V. V. Znachenie priverzhennosti patsientov k lecheniyu pri dlitel'nom prieme atsetilsalitsilovoi kisloty u patsientov, perenesshikh ostryi koronarnyi sindrom: rezul'taty issledovaniya FORPOST. Kardiologiya. 2012;52(9):22-8]
23. Rojas-Fernandez CH, Kephart GC, Sketris IS, Kass K. Underuse of acetylsalicylic acid in individuals with myocardial infarction, ischemic heart disease or stroke: data from the 1995 population-based Nova Scotia Health Survey. The Canadian Journal of Cardiology. 1999;15(3):291-6. PMID: 10202192
24. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care. 1986;24(1):67-74. PMID: 3945130